ELOVL2 and fatty liver disease: The mRNA expression of Elovl2, which is involved in the elongation required for the synthesis of docosahexaenoic acid, was reduced in the livers of obese subjects, and an intervention to improve hepatic steatosis and diabetes upregulated hepatic Elovl2 expression along with hepatic fatty acid oxidation [43,44].